Đánh giá kết quả điều trị ung thư đại tràng di căn không còn chỉ định phẫu thuật triệt căn bằng hóa chất phác đồ Folfoxiri

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Văn Quảng Lê, Thu Thoa Ngô, Lê Huy Trịnh

Ngôn ngữ: vie

Ký hiệu phân loại: 617.554 +Intestine

Thông tin xuất bản: Y học Việt Nam, 2018

Mô tả vật lý: 67-69

Bộ sưu tập: Metadata

ID: 534955

Thêm vào giỏ

Tóm tắt
Chủ đề

Đánh giá kết quả điều trị ung thư đại tràng di căn không còn chỉ định phẫu thuật triệt căn bằng hóa chất phác đồ Folfoxiri trên 39 bệnh nhân. Kết quả cho thấy sau 3 chu kỳ diều trị, tỷ lệ đáp ứng hoàn toàn là 5,1%
đáp ứng một phần là 76,9% và không đáp ứng là 12,8%. Tỷ lệ kiểm soát bệnh là 94,9%. Thời gian sống thêm bệnh không tiến triển trung bình là 13,37 ± 9 tháng. Tỷ lệ sống thêm toàn bộ tại thời điểm 12 tháng và 24 tháng lần lượt là 90% và 76%. Độc tính gan chiếm 52,5% nhưng đều là độ 1.Objectives: To evaluate the treatment results and toxicity profile of triplet combination FOLFOXIRI in the treatment of unresectable metastatic colon cancer patients. Patients and methods: Uncontrolled clinical trial earned on 39 colon cancer patients. Results: After 3 cycles of treatment, the rate of complete response, partial and disease stable rate were 5.1%
76.9% and 12,8% respectively. Disease control rate was 94.9%. After 6 cycles of treatment, these rates were 5.9%
73.5%
11.8% and 91.2% respectively. The median progression free survival was 13.37 ± 9months. The 12 month-survival and 24 month-survival was 90% and 76%. Granulocytopenia is the most considerable side effect, accounting for 48.9%, but mostly grade 1 and grade 2. There are no patients with febrile neutropenia. Liver toxicity, accounted for 52.5%, but all were grade 1. The incidence of chemotherapy induced nausea was 18.3%, none was grade 3 or grade 4. The other toxicities were very low and all were at grade 1. Conclusion: The combination FOLFOXIRI resulted high response rate, improved survival rate and acceptable toxicity for unresectable metastate colon cancer patients.

Tạo bộ sưu tập với mã QR